

# COVID-19 Medication Therapies



Welia Health offers several medication therapies for individuals who have tested positive for COVID-19. Use of these medications is prioritized based on those who are most at risk of severe COVID-19 complications.

| Name                              | Paxlovid  | Molnupiravir  | Bebtelovimab  |
|-----------------------------------|---|---|---|
| Type                              | Antiviral   | Antiviral   | Monoclonal antibody   |
| Authorized use(s)                 | Treatment of mild to moderate symptoms in high-risk patients with COVID-19 symptoms.  | Treatment of mild to moderate symptoms in high-risk patients with COVID-19 symptoms.  | Treatment of mild to moderate symptoms.   |
| Age eligibility                   | Ages 12 years and older   | Ages 18 years and older   | Ages 12 years and older   |
| Weight eligibility                | 88 pounds or more   | 88 pounds or more   | 88 pounds or more   |
| Other criteria for treatment      | <ul style="list-style-type: none"> <li>• Test positive for SARS-CoV-2</li> <li>• Be within 5 days of the start of symptoms</li> <li>• Not pregnant or breastfeeding*</li> <li>• Patient must not be hospitalized</li> </ul>               | <ul style="list-style-type: none"> <li>• Test positive for SARS-CoV-2</li> <li>• Be within 5 days of the start of symptoms</li> <li>• Not pregnant or breastfeeding</li> <li>• Patient must not be hospitalized</li> </ul>                    | <ul style="list-style-type: none"> <li>• Test positive for SARS-CoV-2</li> <li>• Be within 7 days of the start of symptoms</li> <li>• Patient must not be hospitalized</li> <li>• Alternative treatment options are unavailable or not appropriate</li> </ul>     |
| Emergency Use Authorization (EUA) | The Food and Drug Administration has issued Emergency Use Authorizations for all listed therapies. They may not be appropriate for all individuals. Learn more by downloading and reviewing fact sheets using the links provided.         |   |   |
| EUA Fact Sheet (English)          | Fact Sheet for Patients And Caregivers Emergency Use Authorization (EUA) Of Paxlovid For Coronavirus Disease 2019 (COVID-19) <a href="https://www.fda.gov/media/155051/download">fda.gov/media/155051/download</a>                        | Fact Sheet for Patients And Caregivers Emergency Use Authorization (EUA) Of Molnupiravir For Coronavirus Disease 2019 (COVID-19) <a href="https://www.fda.gov/media/155055/download">fda.gov/media/155055/download</a>                        | Fact Sheet for Patients And Caregivers Emergency Use Authorization (EUA) Of Bebtelovimab for Coronavirus Disease 2019 (COVID-19) <a href="https://www.fda.gov/media/156153/download">https://www.fda.gov/media/156153/download</a>                                |
| EUA Fact Sheet (Spanish)          | Hoja de Datos para Pacientes y Cuidadores Autorización de Uso de Emergencia (EUA) de Paxlovid para la Enfermedad por el Coronavirus 2019 (COVID-19) <a href="https://www.fda.gov/media/155075/download">fda.gov/media/155075/download</a> | Hoja de Datos para Pacientes y Cuidadores Autorización de Uso de Emergencia (EUA) de Molnupiravir para la Enfermedad por el Coronavirus 2019 (COVID-19) <a href="https://www.fda.gov/media/155115/download">fda.gov/media/155115/download</a> | Hoja informativa para pacientes, padres y cuidadores Autorización de uso de emergencia (EUA) de bebtelovimab para la enfermedad por coronavirus 2019 (COVID-19) <a href="https://www.fda.gov/media/156155/download">https://www.fda.gov/media/156155/download</a> |
| Contact us                        | If you are interested in any of these treatments, please call the clinic at <b>320.679.1313</b> and select option 2.  |   |   |

\* Pregnant women will require an informed consent visit with a physician or advanced practice provider.